Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Lotiglipron

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Pfizer · Phase 2 · Terminated · Enrollment 902

NCT05579977

EudraCT 2022-002834-15

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
PF-07081532 20 mg T2DMn/rn/rn/rn/r
PF-07081532 40 mg T2DMn/rn/rn/rn/r
PF-07081532 80 mg T2DMn/rn/rn/rn/r
PF-07081532 160 mg T2DMn/rn/rn/rn/r
PF-07081532 260 mg T2DMn/rn/rn/rn/r
Placebo T2DMn/rn/rn/rn/r
PF-07081532 80 mg Obesityn/rn/rn/rn/r
PF-07081532 140 mg Obesityn/rn/rn/rn/r
PF-07081532 200 mg Obesity (Option 1)n/rn/rn/rn/r
PF-07081532 200 mg Obesity (Option 2)n/rn/rn/rn/r
PF-07081532 260 mg Obesityn/rn/rn/rn/r
Rybelsus 14 mg T2DMn/rn/rn/rn/r
Placebo Obesityn/rn/rn/rn/r

Not shown

  • PF-07081532 20 mg T2DM: endpoint not reported
  • PF-07081532 40 mg T2DM: endpoint not reported
  • PF-07081532 80 mg T2DM: endpoint not reported
  • PF-07081532 160 mg T2DM: endpoint not reported
  • PF-07081532 260 mg T2DM: endpoint not reported
  • Placebo T2DM: endpoint not reported
  • PF-07081532 80 mg Obesity: endpoint not reported
  • PF-07081532 140 mg Obesity: endpoint not reported
  • PF-07081532 200 mg Obesity (Option 1): endpoint not reported
  • PF-07081532 200 mg Obesity (Option 2): endpoint not reported
  • PF-07081532 260 mg Obesity: endpoint not reported
  • Rybelsus 14 mg T2DM: endpoint not reported
  • Placebo Obesity: endpoint not reported